Mogamulizumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.
Mogamulizumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
Drug name | Poteligeo® |
INN | Mogamulizumab |
API type | Mogamulizumab is produced in Chinese hamster ovary cells by recombinant DNA technology. |
Pharmacotherapeutic group | Antineoplastic and immunomodulating agents, monoclonal antibodies |
ATC code | L01FX09 |
Target of antibody | CCR4, a G protein-coupled receptor for CC chemokines |
General function | |
Short description | Mogamulizumab is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. |
Pharmacodynamic properties (Mechanism of action; Source EMA document) | Mogamulizumab is a defucosylated, humanised IgG1 kappa immunoglobulin that selectively binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs including the skin, resulting in depletion of the target cells. CCR4 is expressed on the surface of some cancer cells including T cell malignancies, such as MF and SS in which CCR4 expression is inherent. |
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | The pharmacokinetics (PK) of Mogamulizumab was evaluated in adult patients with T-cell leukaemia-lymphoma (ATL) and CTCL over a dose range of 0.01 to 1 mg/kg administered as multiple doses of Mogamulizumab every week or every 2 weeks, and included the recommended 1.0 mg/kg dose and regimen. |
Original license holder | Kyowa Kirin Holdings B.V. Bloemlaan 2 2132NP Hoofddorp Netherlands |
Marketing authorisation numbers | EU/1/18/1335/001 |
Marketing authorisation holder | Kyowa Kirin Holdings B.V. Bloemlaan 2 2132NP Hoofddorp Netherlands |
Name of the manufacturer of the biological active substance | Kyowa Kirin Co., Ltd. Takasaki Plant 100-1 Hagiwara-machi, Takasaki-shi, Gunma, 370-0013 Japan |
Name and address of the manufacturer(s) responsible for batch release | allphamed PHARBIL Arzneimittel GmbH Hildebrandstr. 10-12 37081 Göttingen Germany |
Max shelf life | 3 years |
Storage conditions | 2°C – 8°C |
List of excipients | Citric acid monohydrate Glycine Polysorbate 80 Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment) Water for injections |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany